Sponsored by
Angiogenesis Weekly, Dec 24, 2004 p10
2004 DEC 24 - (NewsRx.com & NewsRx.net)
"We have previously shown that topotecan, a topoisomerase I poison,
inhibits hypoxia-inducible factor (HIF)-1alpha protein accumulation
by a DNA damage-independent mechanism. Here, we report that daily
administration of topotecan inhibits HIF-1alpha protein expression
in U251-HRE glioblastoma xenografts," reported investigators in the
United States.
"Concomitant with HIF-1alpha inhibition, topotecan caused a
significant tumor growth inhibition associated with a marked
decrease of angiogenesis and expression of HIF-1 target genes in
tumor tissue," said A. Rapisarda and colleagues, U.S. National
Cancer Institute, DTP Tumor Hypoxia Laboratory.
"These results provide a compelling rationale for testing topotecan
in clinical trials to target HIF-1 in cancer patients," they
suggested.
Rapisarda and colleagues published their study in Cancer Research
(Schedule-dependent inhibition of hypoxia-inducible factor-1 alpha
protein accumulation, angiogenesis, and tumor growth by topotecan in
U251-HRE glioblastoma xenografts. Cancer Res, 2004;64(19):6845-
6848).
For additional information, contact G. Melillo, NCI, DTP Tumor
Hypoxia Laboratory, Bldg 432, Room 218, Frederick, MD 21702, USA.
The publisher of the journal Cancer Research can be contacted at:
American Association for Cancer Research, 615 Chestnut St., 17TH
Floor, Philadelphia, PA 19106-4404, USA.
The information in this article comes under the major subject areas
of Hypoxia, Oncology, Cancer, and Cancer Therapy.
This article was prepared by Angiogenesis Weekly editors from staff
and other reports. Copyright 2004, Angiogenesis Weekly via
NewsRx.com & NewsRx.net.